Selected article for: "alveolar damage and inflammatory response"
Author: Pinna, Simone Mornese; Scabini, Silvia; Corcione, Silvia; Lupia, Tommaso; De Rosa, Francesco G
Title: COVID-19 pneumonia: do not leave the corticosteroids behind!
  • Cord-id: 2zhq81w9
  • Document date: 2021_3_12
    • ID: 2zhq81w9
    Snippet: The host inflammatory response is critical in the progression of lung injuries in patients with SARS-CoV-2. Corticosteroids (CS) have been widely used as immunomodulating agents, but the right timing, dosage and type of molecule are unknown. In fact, the early use of CS could facilitate the viral replication but late administration may not prevent the alveolar damage. Nevertheless, a short administration of high doses of CS in the early stage of the inflammatory phase resulted in favorable outco
    Document: The host inflammatory response is critical in the progression of lung injuries in patients with SARS-CoV-2. Corticosteroids (CS) have been widely used as immunomodulating agents, but the right timing, dosage and type of molecule are unknown. In fact, the early use of CS could facilitate the viral replication but late administration may not prevent the alveolar damage. Nevertheless, a short administration of high doses of CS in the early stage of the inflammatory phase resulted in favorable outcomes. Noteworthy, some inhaled CS inhibited in vitro the viral replication of SARS-CoV-2. We aimed to define the place in therapy for CS in COVID-19 infection describing the features of patients who may benefit from their administration.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adaptive immune response innate: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and administration timing: 1
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute ards respiratory distress syndrome and low quality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and low quality evidence: 1, 2, 3, 4, 5, 6, 7, 8
    • adaptive immune response and low oral bioavailability: 1
    • administration timing and low quality: 1
    • adrenal suppression and low quality: 1